Generics, new profit protection for drugs developers.

When giant firms set out to sell generic versions of their own branded products, they sure have a competitive edge over smaller independent generics makers.

Bigger is better in this case. Not only big pharmaceutical companies can easily save time and money in their production processes, the product is unquestionable when reproducing its own formulations.

You don't have to be convinced that innovative firms have their finances established. Production money is readily available than small independent firms to spend on developing and producing drugs, and then more drugs.

Major firms, or the original brand-name producers already have study data all communicated through, contracted bulk chemical sources, and manufacturing processes in place. They don't have to go to extremes to prove to the FDA that they can produce the drugs again.  They can quickly submit ANDAs and bring their generics version to the market. 

Talk about saving money and time, what they do to launch the generics is much less expensive and more quickly than what any small independent firms have to go through. What this means to the consumer like you is that, you in turn will save too, giving that the price of generics is under control.

But this is not all why big pharmas win over the generics market. The professionals too may be on their side. Pharmacists may be more likely to buy generic formulations from their original brand-name manufacturers. Their take is that, these generic versions will most likely be identical to the brand-name products.

Regardless how other firms claim to produce the brand name equivalents, drug development is a layered process. From reagents preparation to equipment capacity, and quality and assurance control, anything could go wrong down the line. Besides all the other factors, there is definitely a learning curb when another company comes in to try and reproduce someone else's pill.